Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

The Gillmore staging system stratifies ATTR‑CM prognosis using serum NT‑proBNP and estimated glomerular filtration rate.

NT-proBNP
≤ 3000 pg/mL0> 3000 pg/mL+1
eGFR
≥ 45 mL/min/1.73 m²0< 45 mL/min/1.73 m²+1

适用指征

Used to stage confirmed ATTR‑CM into prognostic groups with NT‑proBNP and eGFR to estimate survival and guide timing of therapy and referral. Applicable to both ATTRwt and ATTRv. Stage I (NT‑proBNP ≤3000 ng/L, eGFR ≥45 mL/min), II (intermediate), III (NT‑proBNP >3000 ng/L and eGFR <45 mL/min) stratifies mortality risk (HR 2.05–3.80 vs stage I) 1 [Level II evidence].

洞见与注意事项

Stratifies prognosis using NT‑proBNP ≤/ >3000 ng/L and eGFR ≥/ <45 mL/min, predicting median survival of ~69, 47, and 24 months for stages I–III respectively 1 [Level I evidence]. Use cautiously because survival estimates predate modern therapies, may underestimate risk in advanced HF or cardiorenal syndrome, and should not guide therapy eligibility alone per ACC consensus 2 [Level III evidence].